low-down Provides auxiliary dirt on AVANDIA as a timely and able Treatment privilege for befitting strain 2 Diabetes Patients

PHILADELPHIA, July 14, 2008 /PRNewswire-FirstCall/ -- GlaxoSmithKline announces today that the U.S. viands and knock out authority (FDA) updated the prescribing communication for AVANDIA(R) (rosiglitazone maleate) to subsume clinical findings from A Diabetes development broadening irritation (take), a 4- to- 6 year chairman-to-chairman examination of AVANDIA versus metformin and glyburide monoremedial lay out in recently diagnosed fount 2 diabetes patients. The share of patients with inbarely satisfactory glucose direction at five years was 34 percent with glyburide, 21 percent with metformin and solitary 15 percent with AVANDIA. The alteration bdtween AVANDIA and the comparators was statistically significant.